Insupen Original
NHS England recommends prescribing pen needles under £5 per box1. In a recent analysis, we found that less than 5% of CCGs have a mean average price of less than £52.
Insupen Original is priced at £2.49 (Pack of 100), complies with ISO 11608 and additional self-imposed quality tests, to ensure quality without compromise3,4.
From June 2022, we are introducing a 4mm x 33G needle to the range making Insupen Original the finest and most cost-effective pen needle range on the market. The 4mm x 33g offers patients the option of a pen needle designed to minimise discomfort at a ground-breaking sustainable price to the NHS of £2.49.
Make prescribing savings quickly
Spirit offers a FREE implementation service to drive down the cost of prescribing, without impacting your valuable time and resources.
Cost savings
The average CCG can save 43% on their annual pen needle spend by adopting Insupen Original2.
Support
Making use of our Active Implementation service has been proven to deliver 700% greater savings than when leaving prescription changes to be managed at practice level without support5. We are experts at mobilisation and do the work for you. Other patient reviews can be conducted at the same time.
Learn more about Active Implementation
Product details
Insupen Original is available in 5 lengths and 5 gauges to match patient need. They are precision engineered to reduce friction points and have a wide internal diameter for efficient insulin administration.
Supporting materials
Download our Insupen Original information leaflet.
References:
1. Items which should not routinely be prescribed in primary care: Guidance for CCGs version 2, June 2019 NHS England Publishing Approval Reference 000608
2. Insulin Pen Needle Cost Savings Analysis. Data on file, Spirit Healthcare, Dec 2021
3. Data on file, Spirit Healthcare. Pikdare quality standards and testing data, supplied April 2020
4. Comparison of usability and Patient Preference for insulin Pen Needles produced with different production Techniques:”Thin-Wall” Needles compared to “Regular-Wall” Needles: An Open-Label Study, Thorsten Siegmund, M.D., Hannes Blankenfeld, M.D., and Petra-Maria Schumm-Draeger,M.D.,
Diabetes Technology & Therapeutics. August 2009,11 (8):523-528. doi: 10.1089/dia. 2009. 0048. Published in Volume: 11 Issue 8: August 21, 2009
5. Jim Swift et al, “Implementing formulary change in diabetes”, British Journal of Healthcare Management, Vol. 23, No. 4
How much could you save?
Try our cost calculator below. Based on the products we have available in our portfolio it will demonstrate how much money we can potentially save your ICB/ICS, Health Board or Local Commissioning Group.
This is an overview of the savings across the diabetes range, which are ready to go and easy to implement products. We can also look at savings for individual products within the prescribing data.
As well as highlighting the therapy areas where spend can be significantly reduced, we have also included Quick Wins savings, which are ready to go, easy to implement, minimal resource dependent products.
Based on ICB prescribing data from Nov 2022 – Oct 2023 with a 70% switch from current prescribing to comparable products from Spirit Healthcare.